Nuvaxovid Approval Boosts Novavax
This is a Nuvaxovid news story, published by Yahoo Finance, that relates primarily to BofA news.
Nuvaxovid news
For more Nuvaxovid news, you can click here:
more Nuvaxovid newsBofA news
For more BofA news, you can click here:
more BofA newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novavax. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest NVAX news, AI stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
NuvaxovidInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Health
Health
BofA Reiterates Hold Rating on Novavax (NVAX) Stock

81% Informative
BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. ( NASDAQ : NVAX ) stock, setting a price target of $ 10 .
The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025 .
VR Score
81
Informative language
80
Neutral language
51
Article tone
formal
Language
English
Language complexity
55
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
1
Affiliate links
no affiliate links